Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
NASA says Maven spacecraft that was orbiting Mars has gone silent - 2Full Supreme Court to hear challenge to Judicial Selection Committee law
- 3I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- 4American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- 5The Best 15 Applications for Efficiency and Association
- Instructions to Guarantee Kids Foster Solid Dental Propensities
- There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?
- Artemis II astronauts arrive at Florida launch site for first moon trip in 53 years
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- 'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1
- Etymological Experiences on the Wireless transmissions: A Survey of \Learning in a hurry\ Language Web recording
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- 4 Excellent Remote Headphones of 2024
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
